Trying to decide whether to hold, buy, or walk away from Cardinal Health stock? You’re not alone, and for good reason. After all, the company’s shares have defied gravity lately, boasting a one-year surge of 48.1% and a remarkable 301.6% gain over the past five years. Even this year alone, Cardinal Health is already up by 37.2%. Clearly, something more than luck is at play here.
If you’ve been tracking recent moves, you’ve probably noticed the healthy 3.5% gain in the past week, capping off a month that saw an additional 4.7% rise. These bumps have been fueled by growing optimism around Cardinal Health’s pharmaceutical distribution business and industry changes that favor the supply chain giants. Investors seemed especially optimistic following the company’s strategic partnerships and initiatives to streamline operations in response to shifting healthcare trends. These moves have signaled to the market that Cardinal is positioning itself ahead of the curve, with both risk and opportunity reflected in the current price.
But let’s not ignore valuation, which is where things get especially interesting for Cardinal Health. Our latest score is a 4 out of 6, which is a strong sign the stock is undervalued on most, but not all, classic checks. Deciding what that’s really worth means weighing different valuation lenses, and in the next section, we’ll break down exactly how those numbers add up. But stick around, because understanding valuation in a rapidly changing market may require an even sharper tool than the usual formulas.
Cardinal Health delivered 48.1% returns over the last year. See how this stacks up to the rest of the Healthcare industry.
A Discounted Cash Flow (DCF) model estimates a company’s value by projecting its expected future cash flows and then discounting those amounts back to their present value. This approach aims to answer what the business is truly worth today, based on where its cash generation is headed over time.
For Cardinal Health, recent data shows the company generated $1.87 billion in Free Cash Flow in the last twelve months. Analyst estimates suggest steady growth ahead, with projected FCF rising to $3.03 billion by 2026 and reaching as high as $5.52 billion by 2030. It is important to note that while direct analyst forecasts extend just five years, extrapolations beyond that point are provided for a broader long-term view.
Using all available projections and discounting them back to their present value, the intrinsic value calculated for Cardinal Health is $584.46 per share. Compared to the company’s current share price, this implies a substantial discount of about 72.3%. This may be a strong indicator that the stock is undervalued based on future cash flows.
Result: UNDERVALUED
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Cardinal Health.
CAH Discounted Cash Flow as at Oct 2025
Our Discounted Cash Flow (DCF) analysis suggests Cardinal Health is undervalued by 72.3%. Track this in your watchlist or portfolio, or discover more undervalued stocks.
The Price-to-Earnings (PE) ratio is a widely used valuation metric for profitable companies like Cardinal Health. It offers a practical snapshot of how much investors are willing to pay today for a dollar of earnings, making it particularly useful when assessing reliable, established businesses in the healthcare sector.
A company’s growth prospects and risk profile can significantly influence what PE ratio is considered “normal” or “fair.” Generally, faster earnings growth or lower risk commands a higher PE multiple, while higher risk or lower growth leads investors to discount the stock with a lower multiple. That is why context is so important when interpreting PE ratios.
Currently, Cardinal Health trades at a PE ratio of 24.6x. This is slightly above the healthcare industry average of 21.6x but closely aligned with the average for similar peers at 25.6x. However, rather than just comparing with peers or the industry, Simply Wall St’s proprietary “Fair Ratio” provides a richer picture. This proprietary measure, 25.2x for Cardinal Health, accounts for factors like earnings growth, profit margin, company size, risks, and industry norms, giving a more nuanced sense of appropriate valuation. Because this Fair Ratio incorporates more information than a simple industry or peer comparison, it is especially helpful for investors looking beyond surface-level multiples.
Stacking Cardinal Health’s current PE of 24.6x against the Fair Ratio of 25.2x, the two are remarkably close. The stock’s valuation today is about in line with what we would expect given its fundamentals and outlook.
Result: ABOUT RIGHT
NYSE:CAH PE Ratio as at Oct 2025
PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.
Earlier, we mentioned there might be an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is simply the story you believe about a company’s future, combining your own perspective on how Cardinal Health will perform with numbers like its expected revenues, earnings, and margins.
This approach connects the dots between what’s happening in the real world, what you think it means for Cardinal Health, and what you believe the stock is actually worth. Narratives are not complex tools reserved for finance professionals. They are easy to use and built directly into Simply Wall St’s Community page, where millions of investors share and compare their own stories and assumptions.
By setting your Narrative, you can compare your fair value of Cardinal Health to its live share price, helping you decide confidently when to buy, hold, or sell. And because Narratives update automatically when fresh news or earnings are released, you always have a current, actionable view.
For example, some investors believe rapid automation and pharmaceutical growth justify a fair value as high as $203, while others focus on margin pressures and regulatory risks, estimating a more cautious $150. Narratives let you make sense of these different opinions and craft your own.
Do you think there’s more to the story for Cardinal Health? Create your own Narrative to let the Community know!
NYSE:CAH Community Fair Values as at Oct 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CAH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
